<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04815291</url>
  </required_header>
  <id_info>
    <org_study_id>SCOUT2021</org_study_id>
    <nct_id>NCT04815291</nct_id>
  </id_info>
  <brief_title>Streamlined Localization Using SCOUT® at Biopsy (STREAMLoc )</brief_title>
  <official_title>STREAMLoc- Streamlined Localization Using SCOUT® at Biopsy: An Analysis of Process Improvement, Cost Savings and Enhanced Patient Experience.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merit Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merit Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry is intended to demonstrate the utility of the SCOUT® Surgical Guidance system&#xD;
      to improve workflow and efficiency in Canadian centers diagnosing and treating breast cancer.&#xD;
      The secondary objective is to further evaluate the safety and performance of the SCOUT®&#xD;
      Surgical Guidance system in 500 consented BI-RADS 4C/5 according to the IFU.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Canadian registry is intended to assess the utility of SAVI SCOUT® in the Canadian&#xD;
      public healthcare system where there are limited resources and a conservative approach to&#xD;
      patient and clinician exposure to harm (i.e., radiation, COVID-19 exposure, patient emotional&#xD;
      trauma). By assessing the utility of reflector insertion at the time of biopsy, this study&#xD;
      will be able to measure the impact on patient visits to the breast center for invasive&#xD;
      procedures between biopsy and surgery, and quantify this value to the public healthcare&#xD;
      system. The efficacy and safety of this system will be further assessed, as well as the&#xD;
      acceptance of clinicians and patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of invasive visits</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Number of visits to the breast centre for an invasive procedure between biopsy and surgery</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives SCOUT at biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Receives SCOUT at biopsy</intervention_name>
    <description>SCOUT Reflector</description>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Woman &gt;18 years and &lt; 80 years of age;&#xD;
&#xD;
          2. Classified as Breast Imaging Reporting and Data System (BI-RADS) 4C or 5;&#xD;
&#xD;
          3. Lesion depth is &lt; 6 cm from skin surface;&#xD;
&#xD;
          4. Non-palpable lesions;&#xD;
&#xD;
          5. Informed consent obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multicentric breast cancer;&#xD;
&#xD;
          2. Pregnant or lactating;&#xD;
&#xD;
          3. Known or suspected nickel-titanium allergy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

